Remove 2020 Remove Illness Remove Individual Remove Medical
article thumbnail

Aftershock in Academia: Assessing COVID-19s Impact on Schizophrenia Patients in Academic Medical Centers [Behavioral, psychosocial, and mental illness]

Annals of Family Medicine

Context: The impact of the COVID-19 pandemic on individuals with schizophrenia who are admitted to academic medical centers (AMCs) has not been previously reported. The study is divided into three periods: pre-COVID (Oct 2019 to Mar 2020), COVID (Apr 2020 to May 2023), and post-COVID (Jun 2023 to Dec 2023).

article thumbnail

Episode 155: Antiracism in Medicine Series – Episode 5 – Racism, Power, and Policy: Building the Antiracist Health Systems of the Future

The Clinical Problem Solvers

Understand that collective action and a focus on community, rather than individualism, are most effective in combating racism and achieving health equity. One of the biggest barriers to health equity is the narrow focus on the individual and a failure to see health as a widespread community issue. Published December 2, 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Long Time Coming: DEA Regs Finally Authorize Schedule II Prescription Partial Fills

FDA Law Blog

Three years after that letter, DEA proposed a rule to amend its regulations consistent with CARA on December 20, 2020. In addition, a pharmacist could partially fill a schedule II prescription issued to patients in a Long Term Care Facility or who have a terminal medical illness diagnosis. 21 U.S.C. § 78,282 (Dec.

article thumbnail

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

FDA Law Blog

Lenz, Principal Medical Device Regulation Expert & Sophia R. Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). Gaulkin & Jeffrey N.

article thumbnail

Deprescribing Super Special Part II: Podcast with Elizabeth Bayliss, Ariel Green, and Kevin McConeghy

GeriPal

Today we are coming back for more (or less given the content), talking about the following articles with their lead authors: First up, we talk with Ariel Green about her article in JAMA Network on preferred phrases a clinician may use to explain why they should reduce or stop the medication. That’s huge! Welcome, Ariel. Ariel: Thanks.

article thumbnail

Episode 120: Antiracism in Medicine Series Episode 1 – Racism, Police Violence, and Health

The Clinical Problem Solvers

Trainees may use this foundation to question how this might impact their medical education and think about this educational legacy may be reformed through curricular and structural changes at their institutions. This starts with self-education and a commitment to speak up when blatant examples of racism come up in the work space and beyond.

article thumbnail

Diabetes in Late Life: Nadine Carter, Tamryn Gray, Alex Lee

GeriPal

When I’m on palliative care consults and attending in our hospice unit we have to counsel patients about deprescribing and de-intensifying diabetes medications. What are the risks and rewards of new classes of medications? When I’m on nursing home call, the most common page I receive is for a blood sugar value. How high is too high?